文献速递前列腺癌

人工智能在前列腺癌主动监测活检中检测癌症的应用

Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
PubMed 文献 · BJU Int · 2024-07-04

本研究在180例前列腺癌主动监测(AS)患者中,用AI算法分析2011至2020年的4744张活检切片,检测癌症的敏感性和特异性分别为0.96和0.73,AI判断为良性的切片占63%可无需病理医生判读,但可能漏诊0.55%含癌切片。AI检测的癌症面积与病理医生测量的癌症长度高度相关(r=0.83)。

要点

  • AI算法检测癌症的敏感性0.96、特异性0.73,以原始病理报告为参考。
  • 63%的切片被AI判为良性,可减少病理医生工作量,但可能漏诊0.55%含癌切片。
  • AI检测的癌症面积与病理医生测量的癌症长度高度相关(r=0.83)。

核心结论

  • 基于AI的活检癌症检测算法可用于减少AS队列中病理医生的工作量。
  • AI检测的癌症量与病理医生测量的癌症长度相关性好,且算法在发现小面积癌症方面表现良好。
  • 据作者所知,这是首次报道在AS患者队列中应用基于AI的数字病理算法检测癌症。

研究设计与样本

  • 研究纳入前列腺癌研究国际主动监测(PRIAS)队列中的180例患者,按预先定义的标准进行前瞻性监测。
  • 对2011年至2020年的诊断和再活检切片(n=4744)进行扫描,并由本机构内部基于AI的癌症检测算法分析。
  • 分析算法的敏感性、特异性及预测需主动治疗需求的准确性。
  • 评估诊断时癌症大小、前列腺特异性抗原(PSA)水平和PSA密度的预后价值。

主要发现

  • AI算法正确检测癌症区域的敏感性为0.96,特异性为0.73,以原始病理报告诊断作为参考方法。
  • 病理医生估计的癌症面积与AI检测的癌症大小高度相关(r=0.83)。
  • 使用AI算法后,63%的切片可无需病理医生判读,因其被分类为良性,但存在漏诊0.55%含癌切片的风险。
  • 诊断时活检癌症含量和PSA密度对患者是否继续AS或停止AS接受主动治疗具有预后价值。

临床怎么用

  • 作者认为,基于AI的活检癌症检测算法可用于减少AS队列中病理医生的工作量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate a cancer detecting artificial intelligence (AI) algorithm on serial biopsies in patients with prostate cancer on active surveillance (AS). PATIENTS AND METHODS: A total of 180 patients in the Prostate Cancer Research International Active Surveillance (PRIAS) cohort were prospectively monitored using pre-defined criteria. Diagnostic and re-biopsy slides from 2011 to 2020 (n = 4744) were scanned and analysed by an in-house AI-based cancer detection algorithm. The algorithm was analysed for sensitivity, specificity, and for accuracy to predict need for active treatment. Prognostic properties of cancer size, prostate-specific antigen (PSA) level and PSA density at diagnosis were evaluated. RESULTS: The sensitivity and specificity of the AI algorithm was 0.96 and 0.73, respectively, for correct detection of cancer areas. Original pathology report diagnosis was used as the reference method. The area of cancer estimated by the pathologists correlated highly with the AI detected cancer size (r = 0.83). By using the AI algorithm, 63% of the slides would not need to be read by a pathologist as they were classed as benign, at the risk of missing 0.55% slides containing cancer. Biopsy cancer content and PSA density at diagnosis were found to be prognostic of whether the patient stayed on AS or was discontinued for active treatment. CONCLUSION: The AI-based biopsy cancer detection algorithm could be used to reduce the pathologists' workload in an AS cohort. The detected cancer amount correlated well with the cancer length measured by the pathologist and the algorithm performed well in finding even small areas of cancer. To our knowledge, this is the first report on an AI-based algorithm in digital pathology used to detect cancer in a cohort of patients on AS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Arvidsson I, Svanemur E, Marginean F, et al. Artificial intelligence for detection of prostate cancer in biopsies during active surveillance. BJU Int. 2024. PMID: 38961742. doi:10.1111/bju.16456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。